Change in systolic blood pressure as compared to placebo [mm Hg] from baseline to end of study · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Change in diastolic blood pressure as compared to placebo [mm Hg] from baseline to end of study · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Change in body weight as compared to placebo [kg] from baseline to end of study · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Laxation response: risk of spontaneous rescue‐free bowel movements in the short terma · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone lower dose showed no clear difference in laxation response: risk of spontaneous rescue‐free bowel… compared with higher dose (low certainty).
1 finding from 1 review
Laxation response: risk of spontaneous rescue‐free bowel movements in the medium termb · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
It is very uncertain whether methylnaltrexone lower dose changes laxation response: risk of spontaneous rescue‐free bowel… compared with higher dose (very low certainty).
1 finding from 1 review
Laxation response: patient assessment of change in bowel status at the end of trial · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone lower dose showed no clear difference in laxation response: patient assessment of change in bowel statusgat… compared with higher dose (low certainty).
1 finding from 1 review
Symptoms of opioid withdrawal in the medium term · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone lower dose showed no clear difference in symptoms of opioid withdrawal in the medium term compared with higher dose (low certainty).
1 finding from 1 review
Serious adverse events · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone lower dose showed no clear difference in adverse events compared with higher dose (low certainty).
1 finding from 1 review
PruritusScale from: 0 to 10 · participants with cholestatic pruritus (CP)
1 finding from 1 review
Quality of life ‐ not measured · participants with cholestatic pruritus (CP)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient satisfaction ‐ not measured · participants with cholestatic pruritus (CP)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depression ‐ not measured · participants with cholestatic pruritus (CP)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk for at least one adverse event per patient · participants with cholestatic pruritus (CP)
Summary of findings table ‐ Naltrexone may leads to higher risk for at least one adverse event per patient compared with placebo (low certainty).
1 finding from 1 review
Criminal activity dichotomous ‐ Reincarceration official records · patients with drug‐using offenders
Summary of findings for the main comparisons: Antagonost (Naltrexone) probably leads to lower criminal activity dichotomous ‐ Reincarceration official records compared with no pharmacological (moderate certainty).
1 finding from 1 review
Drug use · patients with drug‐using offenders
Summary of findings for the main comparisons: Antagonost (Naltrexone) showed no clear difference in drug use (objective) urine screen compared with no pharmacological (low certainty).
1 finding from 1 review
Peak withdrawal severity ‐ Naltrexone · opioid dependent adults
1 finding from 1 review
Overall withdrawal severity ‐ Naltrexone · opioid dependent adults
1 finding from 1 review
Completion rate ‐ Naltrexone · opioid dependent adults
1 finding from 1 review
Initiation of naltrexone treatment Number of participants initiating naltrexone · patients with opiate dependent adolescents
Buprenorphine probably leads to higher initiation of naltrexone treatment Number of participants initiating… compared with clonidine (moderate certainty).
1 finding from 1 review